An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Phase of Trial: Phase III
Latest Information Update: 20 Jun 2017
At a glance
- Drugs Cenobamate (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors SK Life Science
- 13 May 2017 This trial has been suspended in Spain.
- 21 Sep 2016 Planned number of patients changed from 490 to 1200.
- 21 Sep 2016 Status changed from not yet recruiting to recruiting.